Alpha Tau Medical Ltd: Strategic Investment and Promising Clinical Milestones Drive Buy Rating

Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Alpha Tau Medical Ltd (DRTS – Research Report). The associated price target remains the same with $9.00.

Yi Chen’s rating is based on several strategic and clinical developments at Alpha Tau Medical Ltd. The company recently secured a significant $36.9 million investment from Oramed Pharmaceuticals, which not only strengthens its financial position but also brings strategic support through a service agreement and governance involvement. This partnership underscores the potential of Alpha Tau’s innovative technology in oncology therapeutics, enhancing investor confidence.
Additionally, Alpha Tau is poised for multiple clinical and regulatory milestones in 2025, including trials and approvals in various cancer treatments. The company’s promising interim results in pancreatic cancer trials, demonstrating a high disease control rate and favorable overall survival compared to historical data, further support the Buy rating. These factors collectively suggest a strong growth trajectory for Alpha Tau, justifying the positive outlook.

Chen covers the Healthcare sector, focusing on stocks such as Opko Health, Vivani Medical, and Harrow Health. According to TipRanks, Chen has an average return of -17.8% and a 27.78% success rate on recommended stocks.